Alfonso Gutierrez-Aguado

Dr. Alfonso Gutierrez-Aguado

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
TVTatiana Vidaurre
Tatiana Vidaurre
CSCarlos Santos
Carlos Santos
HGHenry Gómez
Henry Gómez
GSGustavo Sarria
Gustavo Sarria
EAEdgar Amorin
Edgar Amorin
JAJulio Abugattas
Julio Abugattas

14 December 2014 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
EMEdward Mezones-Holguín
Edward Mezones-Holguín
RBRafael Bolaños-Díaz
Rafael Bolaños-Díaz
VSVictor Edgar Fiestas Solórzano
Victor Edgar Fiestas Solórzano
CSCésar Sanabria
César Sanabria
AGAlfonso Gutierrez-Aguado
Alfonso Gutierrez-Aguado
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
Introduction: Pneumococcal pneumonia (PP) has a high burden of morbimortality in children. Use of pneumococcal conjugate vaccines (PCVs) is an effective preventive measure. After PCV 7-valent (PCV7) withdrawal, PCV 10-valent (PCV10) and PCV 13-valent (PCV13) are the alternatives in Peru. This study aimed to evaluate cost effectiveness of these vaccines in preventing PP in Peruvian children <5 years-old. Methodology: A cost-effectiveness analysis was developed in three phases: a systematic evidence search for calculating effectiveness; a cost analysis for vaccine strategies and outcome management; and an economic model based on decision tree analysis, including deterministic and probabilistic sensitivity analysis using acceptability curves, tornado diagram, and Monte Carlo simulation. A hypothetic 100 vaccinated children/vaccine cohort was built. An incremental cost-effectiveness ratio (ICER) was calculated. Results: The isolation probability for all serotypes in each vaccine was estimated: 38% for PCV7, 41% PCV10, and 17% PCV13. Avoided hospitalization was found to be the best effectiveness model measure. Estimated costs for PCV7, PCV10, and PCV13 cohorts were USD13,761, 11,895, and 12,499, respectively. Costs per avoided hospitalization were USD718 for PCV7, USD333 for PCV10, andUSD 162 for PCV13. At ICER, PCV7 was dominated by the other PCVs. Eliminating PCV7, PCV13 was more cost effective than PCV10 (confirmed in sensitivity analysis). Conclusions: PCV10 and PCV13 are more cost effective than PCV7 in prevention of pneumonia in children <5 years-old in Peru. PCV13 prevents more hospitalizations and is more cost-effective than PCV10. These results should be considered when making decisions about the Peruvian National Inmunizations Schedule.

2 November 2022 in International Journal of Medical Informatics
Verified
Journal Article
Open access
AGAlfonso Gutierrez-Aguado
Alfonso Gutierrez-Aguado
WCWalter H. Curioso
Walter H. Curioso
JMJosé Carlos Machicao
José Carlos Machicao
HEHans Eguia
Hans Eguia
Nowadays it is necessary to strengthen health information systems and data-based solutions. However, there are few graduate training programs in Peru to use tools and methods of data science applied in public health. This article describes the development process and the initial assessment regarding the experience of the participants in an international multidisciplinary diploma in data intelligence for pandemics and epidemics preparedness, which was carried out from January to May 2021. The diploma was structured in 7 modules and 40 Peruvian professionals participated, of which 11 (27.5%) were women, and 16 (40%) came from regions outside of Lima and Callao. We discussed the need to strengthen institutional and health professionals' capacity to adequately manage large volumes of data, information, and knowledge through the application of emerging technologies to optimize data management processes to improve decision-making in health.

1 August 2016 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
Ericson L GutierrezEricson L Gutierrez
Ericson L Gutierrez
MPMarina Piazza
Marina Piazza
AGAlfonso Gutierrez-Aguado
Alfonso Gutierrez-Aguado
GHGisely Hijar
Gisely Hijar
GCGloria Carmona
Gloria Carmona
EGErnesto Gozzer
Ernesto Gozzer
This article analyzes some examples about how the Ministry of Health of Peru has used evidence for policy and program formulation, implementation and evaluation. It describes the process by which health budget programs are based and strengthened with scientific evidence. Provides an overview about how the development of clinical guidelines methodology is facilitating the generation of high quality evidence based clinical guidelines.It presents some examples of specific information needs of the Ministry of Health to which the Instituto Nacional de Salud has responded, and the impact of that collaboration. Finally, the article proposes future directions for the use of research methodology especially relevant for the development and evaluation of policy and programs, as well as the development of networks of health technology assessment at the national and international level.

12 January 2021 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Open access
PDF file
AGAlfonso Gutierrez-Aguado
Alfonso Gutierrez-Aguado
MPMitsy Pinares-Bonnett
Mitsy Pinares-Bonnett
WSWalter Salazar-Panta
Walter Salazar-Panta
JGJosé Guerrero-Cruz
José Guerrero-Cruz

23 September 2021 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Open access
PDF file
GPGrecia Claussen Portocarrero
Grecia Claussen Portocarrero
AGAlfonso Gutierrez-Aguado
Alfonso Gutierrez-Aguado
Introduction: The rare and orphan diseases (ROD) constitute a current challenge due to the lack of investigation. Objective: Describe the socioeconomic characteristics of rare and orphan diseases (ROD) in Peru, 2019. Methods: Descriptive observational design. The information was obtained from FISSAL administrative records, and an intentional sample of 20 patients was taken to carry out the questionnaire on ROD. For the economic records, a review of the public budget of the MEF was made. The data analysis was descriptive and inferential. Results: There were 454 patients with a total of 49 ROD; of these, the most representative age groups were schoolchildren and young adults (18% each), and the most frequent diagnosis was Tetralogy of Fallot (22%). The questionnaire on ROD reports a median of 7 months in the delay of diagnosis and between 3 and 5 doctors were visited. Likewise, 30% considered that it generated a high to very high expense. It was calculated that the ROD budget constitutes 2.25% of the total budget for high-cost diseases. Likewise, the ROD budget was different between 2014 and 2019. Conclusions: The population with ROD in Peru is not large; however, it requires greater attention to access to health services and a greater budget allocation.